ADVENTRX And Pierre Fabre Announce Manufacturing Agreement For ANX-188 Drug Substance

ADVENTRX Pharmaceuticals, Inc. ANX and Pierre Fabre Medicament today announced they have entered into a multi-year agreement under which Pierre Fabre, as contract manufacturer, will produce the active ingredient in ANX-188 (purified poloxamer 188) for use in clinical trials, including the Phase 3 study of ANX-188 that ADVENTRX plans to initiate this year. For 10 years, Pierre Fabre has successfully developed highly technical manufacturing processes at its FDA-inspected facilities in Pau and Gaillac as a contract manufacturer for international pharmaceutical companies.